NEW YORK, NY / ACCESSWIRE / August 4, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OM Shareholders Click Here: https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30573&wire=1
TGTX Shareholders Click Here: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30573&wire=1
YQ Shareholders Click Here: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30573&wire=1

* ADDITIONAL INFORMATION BELOW *

Outset Medical, Inc. (NASDAQ:OM)

This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.
Lead Plaintiff Deadline : September 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30573&wire=1

According to the filed complaint, (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

TG Therapeutics, Inc. (NASDAQ:TGTX)

TGTX Lawsuit on behalf of: investors who purchased January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline : September 16, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30573&wire=1

According to the filed complaint, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

17 Education & Technology Group Inc. (NASDAQ:YQ)

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
Lead Plaintiff Deadline : September 19, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30573&wire=1

According to the filed complaint, (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE : Levi & Korsinsky, LLP